Compare Eli Lilly And Co (LLY) vs Advanced Drainage Systems Inc (WMS) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

WMS trades at $142.93, down 3.13% today, with a neutral technical signal and mixed analyst sentiment. The company shows strong profitability with a 13.98% net income margin and 24.02% ROE, though revenue remained flat at $2.90B in 2025. Recent earnings beats and a dividend increase signal management confidence, while cash flow turned negative due to increased investing activities.

The outlook is cautiously optimistic with a consensus price target of $184.43 offering 29% upside. Risks include volatile cash flows and competitive pressures, but consistent earnings outperformance and solid balance sheet strength support a favorable risk-reward profile for long-term investors.